4th Person Dies In US From Rare Blood Clot After Receiving Johnson & Johnson COVID Vaccine

A Washington woman has died from a rare blood clotting syndrome after receiving the Johnson & Johnson (JNJ) COVID vaccine, according to Seattle & King County public health authorities.

The woman, who was in her late 30s, is the fourth death reported from the blood clot condition after inoculation of the Johnson & Johnson shot in the U.S. and the first in King County, Washington.

The woman received her vaccination on Aug. 26 and died on Sept. 7. Her death was determined to be caused by thrombosis with thrombocytopenia syndrome, known as TTS. While considered to be a rare condition, it has been identified as an adverse event in some people who receive the Johnson & Johnson COVID vaccine, the public health department said.

Back in April, the Centers for Disease Control and Prevention paused the use of the Johnson & Johnson vaccine for 11 days as it investigated the shot due to blood clot complications. The pause was lifted as it was determined by the agency that the benefits of the vaccine outweighed the risk of the rare condition.

A warning label was placed on the vaccine as a result of the investigation.

As of July 8, the CDC said there have been 38 reported cases of TTS out of the 12.5 million doses of the Johnson & Johnson vaccine that have been administered. The agency also said that the majority of those people with TTS have recovered from their condition.

Complications from the vaccine are “extremely low,” with women aged 18 to 49 most at risk, according to health officials.

Symptoms of blood clots include severe headache, abdominal pain, leg swelling, and shortness of breath. Signs of a blood clot after receiving a vaccination should result in receiving immediate medical treatment.

The Pfizer and Moderna COVID vaccines have not been associated with blood clotting issues, according to the public health agency.

As of Wednesday's premarket hours, shares of Johnson & Johnson were trading at $158.83, down 75 cents, or 0.47%.